VCNX Vaccinex Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VCNX

Price (delayed)

$6.05

Market cap

$7.45M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$43.68

Enterprise value

$6.16M

Vaccinex, Inc. is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The Company's lead drug candidate, pepinemab, blocks SEMA4D, ...

Highlights
Vaccinex's EPS has surged by 55% YoY and by 48% QoQ
Vaccinex's debt has decreased by 49% YoY and by 20% from the previous quarter
The quick ratio has soared by 147% from the previous quarter but it has plunged by 84% YoY
The company's equity has shrunk by 145% YoY but it rose by 40% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.vaccinex.com
Peers: OMER OMGA

Key stats

What are the main financial stats of VCNX
Market
Shares outstanding
1.23M
Market cap
$7.45M
Enterprise value
$6.16M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
4.92
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.81
Earnings
Revenue
$570,000
EBIT
-$20.25M
EBITDA
-$20.13M
Free cash flow
-$17.3M
Per share
EPS
-$43.68
Free cash flow per share
-$37.31
Book value per share
-$2.59
Revenue per share
$1.23
TBVPS
$7.83
Balance sheet
Total assets
$3.63M
Total liabilities
$5.94M
Debt
$247,000
Equity
-$2.31M
Working capital
-$2.57M
Liquidity
Debt to equity
-0.11
Current ratio
0.57
Quick ratio
0.42
Net debt/EBITDA
0.06
Margins
EBITDA margin
-3,531.8%
Gross margin
100%
Net margin
-3,552.8%
Operating margin
-4,014.9%
Efficiency
Return on assets
-571.7%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
-3,552.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VCNX stock price

How has the Vaccinex stock price performed over time
Intraday
0.5%
1 week
-1.31%
1 month
-10.37%
1 year
-91.74%
YTD
-35%
QTD
-18.35%

Financial performance

How have Vaccinex's revenue and profit performed over time
Revenue
$570,000
Gross profit
$570,000
Operating income
-$22.89M
Net income
-$20.25M
Gross margin
100%
Net margin
-3,552.8%
Vaccinex's gross profit has soared by 107% YoY but it has decreased by 28% from the previous quarter
Vaccinex's revenue has soared by 107% YoY but it has decreased by 28% from the previous quarter
Vaccinex's net margin has soared by 51% YoY but it has decreased by 28% from the previous quarter
The operating margin has grown by 45% YoY but it has contracted by 39% from the previous quarter

Growth

What is Vaccinex's growth rate over time

Valuation

What is Vaccinex stock price valuation
P/E
N/A
P/B
N/A
P/S
4.92
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.81
Vaccinex's EPS has surged by 55% YoY and by 48% QoQ
The company's equity has shrunk by 145% YoY but it rose by 40% QoQ
Vaccinex's revenue has soared by 107% YoY but it has decreased by 28% from the previous quarter
VCNX's price to sales (P/S) is 97% less than its 5-year quarterly average of 186.4 and 68% less than its last 4 quarters average of 16.1

Efficiency

How efficient is Vaccinex business performance
Vaccinex's return on sales has surged by 51% YoY but it has decreased by 28% QoQ
Vaccinex's ROA has decreased by 20% from the previous quarter

Dividends

What is VCNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VCNX.

Financial health

How did Vaccinex financials performed over time
The total assets is 39% smaller than the total liabilities
The quick ratio has soared by 147% from the previous quarter but it has plunged by 84% YoY
The total liabilities has soared by 113% YoY but it has contracted by 8% from the previous quarter
Vaccinex's debt is 111% more than its equity
The company's equity has shrunk by 145% YoY but it rose by 40% QoQ
Vaccinex's debt has decreased by 49% YoY and by 20% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.